Asenapine: a clinical overview.

Asenapine is a new, second-generation (atypical) antipsychotic medication with demonstrated efficacy for the acute and maintenance treatment of schizophrenia. It is administered as sublingual tablets in doses of 5 or 10 mg bid. It is well tolerated, with a dropout rate for adverse events similar to that of placebo. Asenapine is associated with a mean weight gain of less than 1 kg over a year and a relatively neutral effect on lipid and glucose levels. It can cause sedation and mild extrapyramidal side effects. Asenapine has a broad receptor affinity profile for most serotonergic, dopaminergic, and adrenergic receptors, with no appreciable affinity for muscarinic receptors. Asenapine may be a helpful treatment option for patients with schizophrenia when weight gain, dyslipidemia, and endocrine abnormalities are a concern.
AuthorsSteven G Potkin
JournalThe Journal of clinical psychiatry (J Clin Psychiatry) Vol. 72 Suppl 1 Pg. 14-8 ( 2011) ISSN: 1555-2101 [Electronic] United States
PMID22217438 (Publication Type: Journal Article, Review)
Copyright© Copyright 2011 Physicians Postgraduate Press, Inc.
Chemical References
  • Antipsychotic Agents
  • Blood Glucose
  • Heterocyclic Compounds with 4 or More Rings
  • Asenapine
  • Antipsychotic Agents (administration & dosage, adverse effects)
  • Blood Glucose (drug effects)
  • Dyslipidemias (chemically induced)
  • Heterocyclic Compounds with 4 or More Rings (administration & dosage, adverse effects)
  • Humans
  • Schizophrenia (drug therapy)
  • Treatment Outcome
  • Weight Gain (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: